Nivolumab 360mg

DRUG2 trials

Sponsors

Michael B. Atkins, MD, NYU Langone Health

Conditions

Advanced Renal Cell CarcinomaBreast Cancer

Phase 2

Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

CompletedNCT03117309

Michael B. Atkins, MDAdvanced Renal Cell Carcinoma

Start: 2017-04-24End: 2025-01-23Updated: 2025-07-10

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

CompletedNCT03742986

NYU Langone HealthBreast Cancer

Start: 2019-05-02End: 2023-06-12Updated: 2023-12-19

Related Papers

Co-expression network-based analysis of gene programs contributing to immune checkpoint inhibitor (ICI) resistance in renal cell carcinoma (RCC).

Journal of Clinical Oncology2025-05-28

Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma

Cancer Discovery2025-02-2422 citations

1017 SLAMF7+ CD8+ exhausted T cell-specific gene signature is associated with resistance to PD1 blockade in renal cell carcinoma

Regular and Young Investigator Award Abstracts2023-10-31

Abstract B013: T cell clonotype expansion is common in advanced renal cell carcinoma but is not associated with altered response to PD-1 blockade

Cancer Research2023-08-15

Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.

Journal of Clinical Oncology2023-06-014 citations

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

Journal for ImmunoTherapy of Cancer2023-03-0128 citations

Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).

Journal of Clinical Oncology2023-02-205 citations

Nivolumab with chemotherapy as neoadjuvant treatment for inflammatory breast cancer.

Journal of Clinical Oncology2022-06-014 citations

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report.

Journal of Clinical Oncology2022-02-166 citations

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).

Journal of Clinical Oncology2021-05-208 citations

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).

Journal of Clinical Oncology2020-05-2056 citations

Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer.

Journal of Clinical Oncology2019-05-201 citations